Johnson & Johnson snares FDA nod for first exon 20-targeted drug in EGFR lung cancer
Just a few short months after Johnson & Johnson’s Janssen unit sent its targeted non-small cell lung cancer drug amivantamab to the FDA, the regulator has come back with a green light—a very specific one. Now christened Rybrevant, the drug is the first-ever treatment for non-small cell lung cancer with a group of epidermal growth factor receptor (EGFR) mutations found in… Read More »